Atlas Venture Life Science Advisors’s Dyne Therapeutics DYN Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$166M	Hold	9,130,465	–	–	20.95%	2
2025 Q4	$179M	Hold	9,130,465	–	–	20.64%	2
2025 Q3	$116M	Hold	9,130,465	–	–	15.35%	3
2025 Q2	$86.9M	Hold	9,130,465	–	–	13.12%	3
2025 Q1	$95.5M	Buy	9,130,465 +1,111,111	+14%	+$15.9M	18.3%	3
2024 Q4	$189M	Sell	8,019,354 -782	-0%	-$23.1K	23.05%	2
2024 Q3	$288M	Hold	8,020,136	–	–	26.71%	1
2024 Q2	$283M	Hold	8,020,136	–	–	29.8%	1
2024 Q1	$228M	Sell	8,020,136 -1,865,313	-19%	-$42.2M	21.01%	1
2023 Q4	$131M	Hold	9,885,449	–	–	15.66%	3
2023 Q3	$88.6M	Hold	9,885,449	–	–	13.72%	3
2023 Q2	$111M	Hold	9,885,449	–	–	13.84%	3
2023 Q1	$114M	Buy	9,885,449 +15,966	+0.2%	+$207K	15.42%	2
2022 Q4	$114M	Buy	9,869,483 +934,581	+10%	+$10.8M	13.78%	3
2022 Q3	$113M	Hold	8,934,902	–	–	12.52%	4
2022 Q2	$61.4M	Hold	8,934,902	–	–	10.26%	3
2022 Q1	$86.1M	Hold	8,934,902	–	–	10.89%	2
2021 Q4	$106M	Buy	+8,934,902	New	+$126M	9.76%	3

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Atlas Venture Life Science Advisors's DYN Position: Q1 2026 in Review

Atlas Venture Life Science Advisors held its Dyne Therapeutics (DYN) position steady in Q1 2026 at 9,130,465 shares worth $166M. The position accounts for 20.95% of the portfolio, ranked #2.

Atlas Venture Life Science Advisors first reported a position in DYN in Q4 2021 and has held it in 18 quarters since. The position peaked at $288M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Atlas Venture Life Science Advisors held 9,130,465 shares of Dyne Therapeutics worth $166M as of Q1 2026.
Atlas Venture Life Science Advisors left its Dyne Therapeutics share count unchanged in Q1 2026.
Dyne Therapeutics made up 20.95% of Atlas Venture Life Science Advisors's portfolio in Q1 2026, its #2 holding.
Atlas Venture Life Science Advisors first reported a position in Dyne Therapeutics in Q4 2021 and has held it in 18 quarters since.
Atlas Venture Life Science Advisors's Dyne Therapeutics position peaked at $288M in Q3 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2026, filed 14 May 2026.